Audentes Therapeutics to Present At Upcoming Investor Conferences

SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:

• Bank of America Merrill Lynch 2017 Health Care Conference
  Gene Therapy & Editing Panel
  May 17, 2017, 1:40 PM PT
  Encore at Wynn Las Vegas, Las Vegas, NV
• UBS Global Healthcare Conference
  Corporate Presentation
  May 22, 2017, 11:00 AM ET
  Grand Hyatt, New York, NY

To access a live webcast of the corporate presentation at the UBS Global Healthcare Conference, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  A replay of the live webcast will remain available on the Audentes website for approximately 30 days following the conference.  A webcast will not be available for the Gene Therapy and Editing Panel at the Bank of America Merrill Lynch 2017 Health Care Conference. 

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Thomas Soloway, CFO
415.818.1040
[email protected]

Media Contact:
Paul Laland
415.519.6610
[email protected]

SOURCE Audentes Therapeutics, Inc.

Related Links

http://audentestx.com